• Journal of Yeungnam Medical Science
• /
• 제37권2호
• /
• pp.112-121
• /
• 2020

Background: Vancomycin-resistant Enterococcus (VRE) has become more common in nosocomial infections, especially in urine samples. However, until now, no treatment regimen has been proven to effectively eradicate urine VRE colonization. Therefore, to evaluate the efficacy of doxycycline in eradicating urine VRE and shortening VRE isolation period, we compared VRE colony detection period between doxycycline-treated and untreated patients. Methods: A retrospective cohort study of 83 patients with VRE colonization in urine cultures was conducted at a tertiary academic hospital from January 2011 to February 2018. Kaplan-Meier survival analysis was used to evaluate eradication rates in the treatment and non-treatment groups. Factors affecting urine VRE colonization persistence were analyzed by multiple logistic regression analysis. Results: The overall rate of VRE eradication during the entire hospital stay was higher in the doxycycline treatment group (90.5%) than in the non-treatment group (58.1%, p=0.014). Survival analysis showed that the 5-, 10-, and 20-day cumulative eradication rates were 78.3%, 100%, and 100% in the doxycycline treatment group, and 18.5%, 45.7%, and 67.8% in the non-treatment group, respectively, thereby indicating that eradication rates were higher in the doxycycline treatment group than in the non-treatment group (p<0.001). Only doxycycline treatment was shown to affect urine VRE colonization persistence in multivariate logistic regression analysis. Conclusion: Doxycycline treatment enhanced the eradication rate of urine VRE colonization and appeared to be useful in shortening VRE isolation period.

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권3호
• /
• pp.180-185
• /
• 2018

Background/Aims: We aimed to compare the outcomes of Helicobacter pylori eradication in patients receiving sequential therapy (ST) depending on the use of ecabet sodium (ES). Materials and Methods: Between January to December 2015, 176 patients randomly received either ST alone (n=72) or 10-day ES therapy combined with ST (n=104). After applying the exclusion criteria, 56 patients were finally assigned to the ST-only group and 84 to the ST with ES group. We retrospectively reviewed and analyzed the H. pylori eradication rate and adverse events between the two groups. Results: Among the 140 patients, 121 (86.4%) achieved successful H. pylori eradication and 24 (17.1%) had adverse events. Eradication was achieved in 50 patients (89.3%) in the ST-only group and in 71 patients (84.5%) in the ST with ES group (P=0.420). No significant difference in the incidence of adverse events was found between the ST-only and ST with ES groups (12.5% vs. 20.2%, respectively; P=0.234). However, the ST with ES group tended to have a higher prevalence of nausea or vomiting than the ST-only group (11.9% vs. 1.8%; P=0.050). Conclusions: ST showed a good H. pylori eradication rate without deteriorating the adverse events regardless of adding ES.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권12호
• /
• pp.4885-4890
• /
• 2015

Background: Helicobacter pylori plays an important role in gastric cancer and typical eradication regimens are no longer effective in many countries, including Thailand. The aim of our study was to compare the effect of Lactobacillus delbrueckii and Streptococcus thermophillus on tailored triple therapy for Helicobacter pylori eradication. Materials and Methods: This prospective single-center study was conducted in Thailand. Helicobacter pylori associated gastritis patients were randomized to 2 groups: group 1 (n=100) was tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid), and group 2 was tailored triple therapy plus pretreatment with probiotic containing yogurt. Successful eradication was defined as both negative histology and negative rapid urease test at four weeks after treatment. Results: A total of 200 infected patients were enrolled. PP analysis involved 194 patients: 96 in the tailored triple therapy with placebo group (group 1) and 98 the in tailored triple therapy plus pretreatment with probiotic containing yogurt group (group 2). Successful eradication was observed in 170 (87.6%) patients; by PP analysis, the eradication rate was significantly higher in group 2 (P = 0.04, 95%CI; 0.02-0.13) than in group 1. ITT analysis also showed that the value was significantly higher in the tailored triple threapy plus pretreatment with probiotic containing yogurt group (group 2) (89/100; 89%) than in the tailored triple therapy with placebo group (group 1) (P= 0.01, 95%CI; 0.04-0.15). In terms of adverse events, there was no significant difference between the two groups. Conclusions: Pretreatment with probiotic containing yogurt can improve Helicobacter pylori eradication rates with tailored triple therapy. Adding probiotics does not reduce adverse effects of the medication.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권22호
• /
• pp.9909-9913
• /
• 2014

Background: Helicobacter pylori (H. pylori) remains an important cause of gastric cancer and peptic ulcer disease worldwide. Treatment of H. pylori infection is one of the effective ways to prevent gastric cancer. However, standard triple therapy for H. pylori eradication is no longer effective in many countries, including Thailand. This study was designed to evaluate the efficacy of adding bismuth and probiotic to standard triple therapy for H. pylori eradication. Materials and Methods: In this prospective single center study, H. pylori infected gastritis patients were randomized to receive 7- or 14-day standard triple therapy plus bismuth with probiotic or placebo. Treatment regimen consisted of 30 mg lansoprazole twice daily, 1 g amoxicillin twice daily, 1 g clarithromycin MR once daily and 1,048mg bismuth subsalicylate twice daily. Probiotic bacteria composed of Bifidobacterium lactis, Lactobacillus acidophilus and Lactobacillus paracasei. Placebo was conventional drinking yogurt without probiotic. CYP2C19 genotyping and antibiotic susceptibility tests were also done. H pylori eradication was defined as a negative $^{13}C$-urea breath test at least 2 weeks after completion of treatment. Results: One hundred subjects were enrolled (25 each to 7- and 14-day regimens with probiotic or placebo). Antibiotic susceptibility tests showed 36.7% metronidazole and 1.1% clarithromycin resistance. CYP2C19 genotyping revealed 40.8%, 49% and 10.2% were rapid, intermediate and poor metabolizers, respectively. The eradication rates of 7- or 14 regimens with probiotics were 100%. Regarding adverse events, the incidence of bitter taste was significantly lower in the 7- day regimen with the probiotic group compared with 7- day regimen with placebo (40% vs. 64%; p=0.04). Conclusions: The 7-day standard triple therapy plus bismuth and probiotic can provide an excellent cure rate of H. pylori (100%) in areas with low clarithromycin resistance such as Thailand, regardless of CYP2C19 genotype. Adding a probiotic also reduced treatment-related adverse events.

• Journal of Preventive Medicine and Public Health
• /
• 제33권3호
• /
• pp.285-298
• /
• 2000

본 연구는 지역사회에서의 소화불량환자의 Helicobacter pylori 양성률, 치료순응률 및 관련요인을 분석하고, 1년 후 요소호기검사로 추적검사를 실시하여 Helicobacter pylori 박멸률 및 관련 요인, Helicobacter pylori 박멸과 증상 호전과의 관계 등을 분석하고, Helicobacter pylori 치료 대안별 비용을 추정하고자 시행되었다. 경주시에 거주하는 30세 이상의 성인을 대상으로 1998년 3월 510명의 소화불량 증상 보유자를 선정하여 혈청검사 (ELISA)를 실시하였다. 대상자 510명 중 혈청검사 양성자 375명(73.5%)중 내시경검사에 동의한 304명에 대하여 CLO검사를 실시하였고, CLO검사 양성자 204명 에 게 tripotassium dicitrato bismuthate, amoxicillin, metronidazole의 3제요법을 실시하였다. 연구결과를 요약하면 다음과 같다. 소화불량자 510명 중 혈청검사에 의한 양성률은 73.5%였고, 혈청학적 검사 양성자 375명 중 내시경검사 수진율은 304명으로 81.1%였다. 이 중 CLO검사 양성자는 204명으로 67.1%였다. Helicobacter pylori 박멸여부를 판정하기 위한 1년 후 추적검사 완료자는 181명으로 88.7%였으며, 이 중 투약순응자는 122명으로 추적완료자의 67.4%였다. 추적완료자 중요소호기검사상 박멸된 대상자는 87명으로 박멸률은 48.1%였다. 투약순응자의 경우 122명 중 70명이 박멸되어 박멸률은 57.4%였다. CLO 양성여부와 대상자의 특성과의 관련성을 분석한 결과 연령, 성별, 주관적 경제적 수준, 흡연, 음주, 비타민 C 복용여부, 규칙적 식사 여부와 관련성이 없었다. 소화불량 증상 중 '상복부 통증' 이외의 모든 증상과 CLO양성 여부와는 유의한 관련성이 있었다(p<0.05). 추적검사 완료자에서 연령과 음주여부는 투약순응률과 유의한 관련성이 있었으나(p<0.05),성별, 흡연여부, 비타민 C 복용여부, 규칙적 식사 여부와는 관련성이 없었다. 치료순응여부와 Helicobacter pylori 박멱률간에는 통계적으로 유의한 관련성이 있었으나(p<0.01), 그외 대상자들의 특성과 Helicobacter pylori 박멸률 간에는 관련성이 없었다. Helicobacter pylori가 박멸된 군과 박멸되지 않은 군의 증상 호전율은 각각 62.1%, 59.6%였으나 통계적으로 유의하지는 않았다. 대안별 비용을 분석하였는데, 대안 I은 소화불량환자 전원에게 3제요법을 시행한 후 요소호기검사를 시행하는 방법이고, 대안 II는 소화불량환자를 대상으로 혈청검사를 시행 후 양성자에게 3제요법을 시행하고 요소호기검사를 시행하는 방법이며, 본 연구에서 적용된 대안 III은 소화불량환자를 대상으로 혈청검사를 시행 후 양성자에게 내시경검사와 CLO검사를 실시하고, 양성자에게 3제요법을 시행한 후 요소호기검사를 시행하는 방법이다. Helicobacter pylori 박멸을 위한 대안별 비용을 분석하면, 1인당 치료 비용은 대안 I 이 61,761원, 대안 II는 51,549원, 대안 III은 58,328원이었다. 대안별 비용과 항생제 내성 문제, 투약대상자의 수 등의 장 단점을 고려할 때 비용면에서는 대안 II가, 투약대상자수, 항생제 내성 문제, 위암의 조기발견 가능성 등을 고려하면 대안 III이 좋은 대안이라 할 수 있다. 지역사회 소화불량환자에서 혈청학적 검사 양성자 중 CLO 양성자율이 67.1%로 높고, 3제요법에 의한 치료율은 48.1%(치료순응자의 치료율은 57.4%)이고, 증상호전율은 60%를 상회하므로, Helicobacter pylori의 높은 감염률을 고려하면 지역사회에서 소화불량환자를 대상으로 한 집단검진 및 박멸사업의 시행은 의의가 있을 것으로 생각된다. 그러나 투약 대상자 선정을 위한 선행 검사와 치료약제의 선택을 위한 추가적인 연구는 필요하다. 또한 치료방침에 따른 투약순응률을 향상시키는 방안이 제시되어야 할 것이다. 향후 지역사회에서의 Helicobacter pylori에 대한 연구가 더 수행되어야 하며, 재감염률 등의 분석을 위 한 코호트를 구축하는 것이 필요하다. 또한 정책의 결정을 위한 근거자료로 활용할 수 있는 비용-편익분석이나 비용-효과분석을 할 수 있는 장기적인 연구들이 수행되어야 할 것이다.

• 미생물학회지
• /
• 제41권3호
• /
• pp.177-182
• /
• 2005

본 연구를 수행하기 전에 H. pylori에 대한 어떠한 치료도 받지 않은 114명의 소화기 궤양 환자들을 내시경 검사를 하는 동안, 114개의 H. pylori 균주를 위 전정부로부터 분리하였다. H. pylori를 검출하기 위하여 rapid urease test, SSA와 cagA 유전자의 PCR증폭을 수행하였고, CagA 발현 검출을 위하여 Western blot을 수행하였다. H. pylori에 감염된 환자들은 omeprazole. clarithromycin (a macrolide), amoxicillin을 모두 사용하는데 3제 요법(triple therapy)으로 치료하였다. 치료가 중단되고 6주 후에 내시경 검사에서 세균 박멸률을 측정하였다. 내성률은 각각 clarithromycin이 $20.2\%$. amoxicillin이 $0.0\%$였다. Clarithromycin 내성은 H. pylori의 23S rRNA 유전자에 있는 A2142G돌연변이에 의한 것이 $87\%$이었다. A2142G돌연변이의 clarithromycin의 MIC값($32\~>256\;{\mu}g\ml$)은 A2143G돌연변이의 MIC값($4\~128\;{\mu}g/ml$)보다 더 높았다. Clarithromycin에 감수성을 가진 H. pylori는 박멸되었으나 clarithromycin내성을 가진 H. pylori는 박멸되지 않았다(P = 0.0001). 이러한 결과들은 CagA 발현에는 어떠한 영향도 받지 않았으며 H. pylori의 clarithromycin 내성은 치료 실패의 가장 중요한 이유임을 제시하였다. 우선적으로 실시되는 생검 배양에 대한 H. pylori의 항생제 감수성 시험은 감염된 환자들에 대한 3제 요법을 선택하기 이전에 필히 실시되어야 하며 국내에서 clarithromycin에 대한 1차 내성의 높은 빈도는 H. pylori의 감염증 치료에 심각한 문제점을 야기시켰다.

• Journal of Digestive Cancer Research
• /
• 제10권2호
• /
• pp.49-55
• /
• 2022

Helicobacter pylori (H. pylori) infection is associated with gastroduodenal diseases such as gastritis, peptic ulcer diseases, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. Furthermore, various extragastroduodenal diseases have been suggested to be related with H. pylori infection. Although no single factor has been considered the cause of gastroesophageal reflux disease (GERD), a negative association was found between the prevalence of H. pylori and GERD severity. Additionally, the role of eradication therapy of H. pylori in reflux esophagitis is controversial, and a significant correlation was found between successful H. pylori eradication rate and reflux esophagitis development. H. pylori infection remains an inconclusive and important issue in GERD. Thus, more experimental studies are necessary to elucidate the potential mechanisms.

• 대한한방내과학회지
• /
• 제33권1호
• /
• pp.39-53
• /
• 2012

Objectives : Many studies have shown that helicobacter pylori (H. pylori) infection is associated with gastroduodenal diseases. The purpose of this report was to evaluate recently published research on the influence of oriental herbal medicine on H. pylori infections. Methods : Recently published literature were systematically compared with their findings of how oriental herbal medical treatment affects H. pylori-associated disease. Results : The eradication rate of H. pylori in oriental herbal medicine groups was 66.93% while it was 66.02% in western medicine groups. In oriental herbal plus western medicine groups, interestingly, the rate increased to 84.78%. On the other hand, the total treatment efficacy rate of H. pylori in oriental herbal medicine groups was 91.27%. The treatment efficacy rate in oriental herbal plus western medicine groups rose to a record 93.22%, which was 15.34% higher than the rate in western medicine groups. In addition, the rate of adverse effects was 2.71%, 4.85%, 15.80% in oriental herbal medicine, western medicine, and oriental herbal plus western medicine groups, respectively. Diarrhea was most frequently observed in oriental herbal medicine groups, while nausea was most frequently observed in the other groups. Conclusions : The results of this study showed that herbal medicinal treatment can increase the rate of H. pylori eradication and improve H. pylori-related gastrointestinal symptoms. These findings suggest that herbal medicine can solve the problems including side effects due to antibiotic resistance of standard triple therapy.

• 대한한방내과학회지
• /
• 제39권6호
• /
• pp.1136-1149
• /
• 2018

Objectives: The aim of this study was to perform a meta analysis of randomized controlled trials (RCTs) that applied Opae-san to peptic ulcer. Methods: The databases NDSL, RISS, KISS, KISTI, Oasis, DBpia, Cochrane, EMBASE, Pubmed, and CNKI were searched to identify RCTs that evaluated the therapeutic response to Opae-san on peptic ulcer. The selected studies were assessed using Cochrane Group's risk of bias tool. Results: 12 RCTs were selected from a total of 312 identified. Combined therapies of Opae-san plus triple therapy were superior to only triple therapy in achieving the effective rate (risk ratio=1.26, 95% CI: 1.17 to 1.35, p<0.001, I2=0%), the helicobacter pylori eradication rate (risk ratio=1.23, 95% CI: 1.12 to 1.34, p<0.001, I2=7%) and the recurrence rate (risk ratio=0.31, 95% CI: 0.12 to 0.82, p=0.02, I2=0%). But only Opae-san was not superior in achieving the effective rate compared to anti gastric secretion drugs. Conclusions: The current evidence suggests that combined therapies of Opae-san plus triple therapy yield a higher effective rate, and helicobacter pylori eradication rate and a lower recurrence rate. However, in most of these studies, it is difficult to evaluate the bias and therefore better designed studies are needed.

• 대한소화기학회지
• /
• 제72권6호
• /
• pp.286-294
• /
• 2018

Background/Aims: The predictive factors of functional dyspepsia (FD) remain controversial. Therefore, we sought to investigate symptom responses in FD patients after Helicobacter pylori (H. pylori) eradication and used predictive factor analysis to identify significant factors of FD resolution at one-year after commencing eradication therapy. Methods: This prospective, multi-center clinical trial was performed on 65 FD patients that met Rome III criteria and had H. pylori infection. Symptom responses and factors that predicted poor response were determined by analysis one year after commencing H. pylori eradication therapy. Results: A total of 63 patients completed the one-year follow-up. When an eradication success group (n=60) and an eradication failure group (n=3) were compared with respect to FD response rate at one year, results were as follows; complete response 73.3% and 0.0%, satisfactory response 1.7% and 0.0%, partial response 10.0% and 33.3%, and refractory response 15.0% and 66.7%, respectively (p=0.013). Univariate analysis showed persistent H. pylori infection (p=0.021), female gender (p=0.025), and medication for FD during the study period (p=0.013) were associated with poor FD response at one year. However, age, smoking, alcohol consumption, and underlying disease were not found to affect response. Finally, multivariate analysis showed that female gender (OR, 4.70; 95% CI, 1.17-18.88) was the sole independent risk factor of poor FD response at one year after commencing H. pylori eradication therapy. Conclusions: Female gender was found to predict poor response in FD patients despite H. pylori eradication. Furthermore, successful H. pylori eradication appears to be associated with FD improvement, but the number of non-eradicated patients was too small to conclude.